Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Leiomyosarcoma 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Sorafenib 110Temozolomide 109Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × PTC596 × Clear all
NCT03206645 2024-04-23

PTC-001

University of Oklahoma

Phase 1 Completed
27 enrolled
Gynecologic

Ovarian Neoplasms

NCT03761095 2024-03-15

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

PTC Therapeutics

Phase 1 Completed
41 enrolled
Sarcoma

Leiomyosarcoma

NCT02404480 2017-12-08

PTC596 in Patients With Advanced Solid Tumors

PTC Therapeutics

Phase 1 Completed
31 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡